ImCheck Therapeutics

📍 Marseille, France🗓 Founded 2015👥 48 employees💰 Last funded Sep 2020
Biotechnology🌐 imchecktherapeutics.com
Website LinkedIn
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Belgium
1
Hong Kong SAR
1
Frequently asked questions
Who invested in ImCheck Therapeutics?
ImCheck Therapeutics has 2 investors on record on gritt.io, 2 mid-stage.
When did ImCheck Therapeutics last raise funding?
The most recent investment in ImCheck Therapeutics recorded on gritt.io was in September 2020.
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded in 2015.
What industry is ImCheck Therapeutics in?
ImCheck Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is ImCheck Therapeutics based?
ImCheck Therapeutics is headquartered in Marseille, France.